Ra Pharmaceuticals is part of the healthcare sector and trades as part of the biotechnology industry. The company CEO is Douglas A. Treco. Ra Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It discovers and develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system.
Previous Intraday Performance:
The RARX shares had a previous change of -1.41% which opened at 21.96 and closed at 21.65. It moved to an intraday high of 22.27 and a low of 21.35.
Over the last five trading days, RARX shares returned 3.14% and in the past 30 trading days it returned -20.05%. Over three months, it changed 9.51%. In one year it has changed 273.92% and within that year its 52-week high was 27.68 and its 52-week low was 5.64. RARX stock is 283.87% above its 52 Week Low.
Our calculations result in a 200 day moving average of 16.86 and a 50 day moving average of 22.28. Right now, RARX stock is trading 28.40% above its 200 day moving average.
The company has a market cap of $913.4m with 42.2m shares outstanding and a float of 41.9m shares. Trading volume was 414,662 shares and has experienced an average volume of 515,992 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.
The last annual reported EPS for Ra Pharmaceuticals was -2.07 which ended on 31st of December 2018. Based on 4 analyst estimates, the consensus EPS for the next quarter is -0.48.
Base on our calculations, the intrinsic value per share is 15.24, which means it might overvalued by -42.05%
The next earnings report will be: 05-23-2019
The growth of the EPS is critical in understanding the current valuation of Ra Pharmaceuticals.
Indicators Also to Watch:
Based on the latest filings, there is 108.40% of institutional ownership.
I calculated the beta to be 0.78
SeekingAlpha: Photronics beats by $0.03, misses on revenue
Based on last reported financials, the company’s return on equity is -47.52%, return on assets is -43.88%, price-to-sales is 370.58 and price-to-book is 4.19.
Company Score Card:
Results are out of six:
2 : Growth Expectations Result
6 : Financial Safety Result
0 : Past Performance Result
0 : Valuation Result
0 : Dividend Safety Result
2 : Overall Result